| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8217151 | International Journal of Radiation Oncology*Biology*Physics | 2015 | 9 Pages |
Abstract
Combined modality immunochemotherapy and RT is well tolerated and effective for treatment of PMBCL. A postchemotherapy 5PS of 4 to 5, rather than 3 to 5, can identify patients at high risk of progression who should be considered for therapy beyond chemotherapy alone after R-EPOCH.
Related Topics
Physical Sciences and Engineering
Physics and Astronomy
Radiation
Authors
Chelsea C. MD, PhD, Bouthaina MD, Mohamed Amin MD, Hubert H. MD, PhD, Colleen MD, Christine F. MS, Valerie MD, Jorge E. MD, Sattva MD, Yasuhiro MD, M. Alma MD, Luis MD, Frederick B. MD, Loretta MD, Francesco MD, Nathan MD, Michelle A. MD, Yago MD, PhD,